Stay updated on Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Sign up to get notified when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.
Latest website image capture
Clouds background image

Latest updates to the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T05:57:30.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed study design and inclusion/exclusion criteria for the DOLATAV study, while adding references to the study's collaborators and a new version revision number.
    Difference
    30%
    Check dated 2025-04-16T16:41:58.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T10:56:42.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T22:48:57.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T15:59:02.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T11:12:08.000Z thumbnail image

Stay in the know with updates to Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Enter your email address, and we'll notify you when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.